AbbVie To Acquire ADC Bio/Pharm Company ImmunoGen for $10.1 Bn
By
AbbVie has agreed to acquire ImmunoGen, a Waltham, Massachusetts-based bio/pharmaceutical company developing antibody drug conjugates (ADCs), for approximately $10.1 billion. ImmunoGen’s commercial product is Elahere (mirvetuximab soravtansine-gynx), an ADC for…